The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
'Every Indian Is Elated With This Recognition': PM Modi As 'Maratha Military Landscapes' Gets UNESCO Tag
Good News: Pune-Nashik Industrial Expressway To Be Built In 3 Years, Will Cut Travel Time To 2.5–3 Hours
Chhattisgarh State Electricity Regulatory Commission Effects Average Hike In Power Tariffs By 1.89%
Mumbai Police Trace 4 Minor Boys Missing From Malvani Madrasa To Ajmer, All Found Safe
(With inputs from Agencies)
